Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

Psychotic experiences are linked to cannabis use in adolescents in the community because of common underlying environmental risk factors.

Authors: Sania Shakoor, Helena M.S. Zavos, Philip McGuire, Alastair G. Cardno, et al
Psychiatry Research, 30 June 2015

Cannabis users are more likely to have psychotic experiences (PEs). The degree to which these associations are driven by genetic or environmental influences in adolescence is unknown. This study estimated the genetic and environmental contributions to the relationship between…

Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.

Authors: Kevin P. Hill
JAMA, 23 June 2015

IMPORTANCE: As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE: To review the pharmacology, indications, and law…

Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.

Authors: Penny F. Whiting, Robert F. Wolff, Sohan Deshpande, Marcello Di Nisio, Steven Duffy, et al
JAMA, 23 June 2015

IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty…

Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids with and without Alcohol.

Authors: Rebecca L. Hartman, Timothy L. Brown, Gary Milavetz, Andrew Spurgin, et al
Clinical Chemistry, June 2015

BACKGROUND: Increased medical and legal cannabis intake is accompanied by greater use of cannabis vaporization and more cases of driving under the influence of cannabis. Although simultaneous Δ(9)-tetrahydrocannabinol (THC) and alcohol use is frequent, potential pharmacokineti…

Use of cannabis in severe childhood epilepsy and child protection considerations.

Authors: Megan Yap, Laura Easterbrook, Jan Connors, Laura Koopmans
Journal of Paediatrics and Child Health, May 2015

The use of medical cannabis in chronic illness is increasingly investigated, yet little is known about its use in paediatric populations. As child protection clinicians are often asked to provide advice around whether parents’ actions to give medical cannabis to their chronica…

Use of Prescription Pain Medications Among Medical Cannabis Patients

Authors: Brian E. Perron, Kipling Bohnert, Angela K. Perone, Marcel O. Bonn-Miller, Mark Ilgen
Journal of Studies on Alcohol and Drugs, May 2015

OBJECTIVE: Management of chronic pain is one of the most common reasons given by individuals seeking medical cannabis. However, very little information exists about the concurrent use of cannabis and prescription pain medication (PPM). This study fills this gap in knowledge by…

Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case report.

Authors: Dimah Saade, Charuta Joshi
Pediatric Neurology, May 2015

BACKGROUND: Malignant migrating partial seizures in infancy is a devastating pharmacoresistent epileptic encephalopathy of unknown etiology characterized by onset in the first 6 months of life, continuous migrating focal seizures with corresponding multifocal electroencephalog…

Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer.

Authors: Eduardo Pérez-Gómez, Clara Andradas, Sandra Blasco-Benito, María M. Caffarel, et al
Journal of the National Cancer Institute, 8 April 2015

BACKGROUND: Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different cancer models. However, the biological role of these receptors in tumor physio-pathology is still unknown. METHODS: We analyzed CB2 cannabinoid receptor protein expressio…

Proapoptotic effect of endocannabinoids in prostate cancer cells.

Authors: O. Orellana-Serradell, C. E. Poblete, C. Sanchez, E. A. Castellón, I. Gallegos, et al
Oncology Reports, April 2015

In the early stages, prostate cancer is androgen‑ dependent; therefore, medical castration has shown significant results during the initial stages of this pathology. Despite this early effect, advanced prostate cancer is resilient to such treatment. Recent evidence shows that…

Phytocannabinoids and epilepsy

Authors: R. G. dos Santos, J. E. C. Hallak, J. P. Leite, A. W. Zuardi, J. A. S. Crippa
Journal of Clinical Pharmacy and Therapeutics, April 2015

WHAT IS KNOWN AND OBJECTIVE: Antiepileptic drugs often produce serious adverse effects, and many patients do not respond to them properly. Phytocannabinoids produce anticonvulsant effects in preclinical and preliminary human studies, and appear to produce fewer adverse effects…

Cannabinoids in late‐onset Alzheimer’s disease

Authors: AIA Ahmed, MA van der Marck, GAH van den Elsen, MGM Olde Rikkert
Clinical Pharmacology & Therapeutics, 8 March 2015

Given the lack of effective treatments for late-onset Alzheimer’s disease (LOAD) and the substantial burden on patients, families, health care systems, and economies, finding an effective therapy is one of the highest medical priorities. The past few years have seen a growing…

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study.

Authors: Marta Di Forti, Arianna Marconi, Elena Carra, Sara Fraietta, Antonella Trotta, Matteo Bonomo, et al
The Lancet Psychiatry, March 2015

BACKGROUND: The risk of individuals having adverse effects from drug use (eg, alcohol) generally depends on the frequency of use and potency of the drug used. We aimed to investigate how frequent use of skunk-like (high-potency) cannabis in south London affected the associatio…